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Dysfunction in energy metabolism—including in pathways localized to the
mitochondria—has been implicated in the pathogenesis of a wide array of disorders,
ranging from cancer to neurodegenerative diseases to type II diabetes. The inherent
complexities of energy and mitochondrial metabolism present a significant obstacle
in the effort to understand the role that these molecular processes play in the
development of disease. To help unravel these complexities, systems biology
methods have been applied to develop an array of computational metabolic models,
ranging from mitochondria-specific processes to genome-scale cellular networks.
These constraint-based (CB) models can efficiently simulate aspects of normal and
aberrant metabolism in various genetic and environmental conditions. Development
of these models leverages—and also provides a powerful means to integrate and
interpret—information from a wide range of sources including genomics, proteomics,
metabolomics, and enzyme kinetics. Here, we review a variety of mechanistic modeling
studies that explore metabolic functions, deficiency disorders, and aberrant biochemical
pathways in mitochondria and related regions in the cell.
Keywords: mitochondria, energy metabolism, constraint-based models, flux balance analysis, Warburg effect,
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INTRODUCTION
Energy-producing metabolic pathways—including those primar-
ily active in mitochondria—are among the most central compo-
nents of eukaryotic life. As such, dysfunction in these pathways
has been implicated in numerous human diseases, including
diabetes, cancer, epilepsy, myopathy, cognitive impairment, and
neurodegenerative disorders [reviewed in DiMauro and Schon
(2003)]. Advances in high-throughput technologies have pro-
vided a wealth of measurements that, when effectively harnessed,
can provide enormous insights into the underlying mechanisms
that give rise to aberrant energy metabolism and associated dis-
eases. Computational modeling, in particular, represents a pow-
erful approach to interrogate metabolism on the systems level and
to efficiently integrate heterogeneous data types such as genomic,
transcriptomic, proteomic, and metabolomic. Here, we highlight
some of the major efforts and successes thus far in modeling
energy metabolism using an approach known as constraint-based
(CB) modeling. We focus heavily on modeling studies of mito-
chondrial function, as this organelle houses many key metabolic
processes related to energy production. Aside from models of
mitochondrial metabolism and related pathways, we also review
the Warburg effect, a long-established cancer phenomenon that
has recently garnered significant attention.
Mitochondria are maternally-inherited, dynamic organelles
present in all cells of the body, excluding the red blood cells.
They vary in number from a few hundred to thousands per cell,
depending upon the cell type and its functions. Mitochondria
play a vital role in cell life, death, and differentiation. They
are centers of adenosine triphosphate (ATP) production and a
multitude of other housekeeping functions such as biosynthesis
of amino acids, oxidation of fatty acids, and apoptosis. The mito-
chondrion has been appropriately called the “powerhouse” of the
cell, and this function has been the focus of intensive research.
Each mitochondrion is a semi-autonomous organelle with its
own DNA and replication machinery. Themitochondrial genome
(mtDNA) is a 16,569 base pair long circular molecule (Anderson
et al., 1981). Since its discovery, mtDNA has been sequenced
across populations to investigate natural variation (Ingman and
Gyllensten, 2006), and various mutations leading to disorders
have been identified (Holt et al., 1988; Wallace et al., 1988; Vieira
et al., 2000). The mtDNA encodes only 13 proteins, while the
nuclear DNA (nDNA) encodes the rest of the mitochondrial
proteins. The complete mitochondrial proteome was originally
estimated to include 1500 proteins, based on quantitative two-
dimensional gel analysis (Lopez et al., 2000). Later, Pagliarini et al.
performed a comprehensive experiment utilizing mass spectrom-
etry, GFP-tagging and machine learning to identify 1098 genes
and respective mitochondria-localized proteins in 14 different
mouse tissues (Pagliarini et al., 2008). This study revealed vari-
ation within each tissue in the number of mitochondria per cell as
well as in mitochondrial gene and protein expression. For exam-
ple, the cells in the heart have three times more mitochondria
as compared to cells in the liver. It was further observed that
while different tissues display variation in mitochondrial gene
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expression, developmentally related organs exhibit higher simi-
larity in theirmitochondrial transcriptome and proteome (Forner
et al., 2006).
The availability of extensive genetic and proteomic informa-
tion has made it possible to catalog the relationship between
mutations in the mtDNA and nDNA and emergent disease
phenotypes. Defective oxidative phosphorylation (OxPhos), for
instance, has been implicated in various respiratory chain dis-
eases, ranging from neonatal lethality to adult-onset of neurode-
generation (DiMauro and Hirano, 2006); Kirby and Thornburn
cataloged mutations in 92 protein-encoding genes causing
OxPhos-related diseases (Kirby and Thorburn, 2008). A similar
study (Smits et al., 2010) noted that there are 200 documented
mutations in the mtDNA and 100 in nDNA among OxPhos-
related genes. In addition to defects in OxPhos genes, other
mitochondrial genes have been implicated in diseases such as
diabetes (DiMauro and Hirano, 2006), Miller syndrome (Ng
et al., 2010), and neurodegenerative diseases [reviewed in Schon
and Przedborski (2011)]. For example, mutations in the mtDNA
replication protein, mtDNA polymerase γ, cause degeneration of
the cerebellum (Hakonen et al., 2008).
The MitoPhenome database, which catalogs mutations in
mtDNA with the resulting diseases, was generated by performing
an extensive literature search (http://www.mitophenome.org).
To date, the database includes 502 hierarchical clinical features
with defects in 174 mitochondria-resident proteins. In addi-
tion to MitoPhenome, other mitochondrial databases such as
MitoP2 (Elstner et al., 2008), MitoCarta (Pagliarini et al., 2008),
MitoMiner (Cotter et al., 2004; Smith and Robinson, 2009), and
MitoProteome (Cotter et al., 2004) have been curated, and these
provide information regarding the mitochondrial genome and
proteome in various organisms and tissues.
The abundance of available experimental data, particu-
larly those coupling large-scale molecular measurements to
resulting disease phenotypes, presents opportunities to achieve
enhanced insight into mitochondrial physiology and disease.
Computational modeling of metabolic functions in the mito-
chondria provides an advantageous means to combine different
data types, and to investigate the effects of genomic and pro-
teomic perturbations on the pathway and genome scales. In
particular, constructing biochemically detailed models allows one
to leverage existing literature and experimental knowledge—
coupled with the enforcement of physical and chemical laws—
to provide a functional context for high-throughput data. In
this way, computational models can be used to help eluci-
date genotype-to-phenotype relationships in mitochondria and
related diseases. CB modeling approaches applied to reaction net-
works in particular have been employed to achieve this goal.
The basic premise of these approaches is that mathematical
constraints are applied to a system, thereby defining an operat-
ing space that best represents the biological and environmental
conditions of interest.
When enough information is available, one can construct a
kinetic model, which establishes a highly constrained mathemat-
ical representation of the reaction network; kinetic modeling is
a well-established approach to simulate mitochondrial function
in silico. A kinetic model typically includes a set of ordinary
differential equations or partial differential equations, describ-
ing the export and import of metabolites and the rate of change
of metabolite concentrations, with associated parameters such as
enzyme capacities and equilibrium or rate constants governing
the metabolic processes. Kinetic models have been built to simu-
late various mitochondrial functions such as ATP production and
beta-oxidation of fatty acids (Korzeniewski, 1998a,b; Cortassa
et al., 2003; Beard, 2005; Modre-Osprian et al., 2009); the devel-
opment of kinetic mitochondrial models to studymetabolism and
disease has recently been reviewed elsewhere (Cortassa and Aon,
2012). Although, kinetic modeling holds promise for its power to
accurately capture biochemical dynamics, the unavailability of the
necessary parameters such as rate constants, enzyme concentra-
tions, initial and steady-state metabolite concentrations, and elec-
trical potential impedes its implementation for many-component
and highly connected biological processes.
Alternatively, stoichometric modeling is a more generalized,
CB approach designed to simulate complex living systems by inte-
grating data from multiple sources and quantitatively analyze the
flux through a cascade of reactions to exhibit a specific phenotype.
Given the widely employed use of “constraint-based (CB) model-
ing” in the systems biology community to denote stoichiometric
modeling, we will henceforth consider this former term distinct
frommore detailed kinetic modeling. In contrast to kinetic mod-
eling, CB modeling requires relatively few parameters and defines
a set of non-excluded states that is consistent with the available
data and applied physico-chemical constraints. As such, these
models can be highly suitable to integrating and interrogating
high-throughput datasets for a biological investigation of inter-
est. Procedures for the construction and analysis of CB models
are well established in microbial species (Feist et al., 2009; Thiele
and Palsson, 2010), and these approaches have recently been gain-
ing increased attention for the study of human metabolism and
disease.
Here we present various applications of CBmodeling to under-
stand functioning of the mitochondria under normal and dis-
ease conditions (Figure 1). These studies include modeling of
the tricarboxcylic acid (TCA) cycle, ATP production, and other
processes in energy metabolism, with particular focus on how
corresponding metabolic states relate to diseases such as diabetes,
ischemia, α-ketoglutarate deficiency, and others (Ramakrishna
et al., 2001; Vo et al., 2004; Thiele et al., 2005). While CB models
of energymetabolism and associated diseases have predominantly
focused on pathways of the mitochondria, recent studies have
also more generally explored the implications of dysfunctional
energy pathways in neurodegenerative diseases and in various
cancers. In particular, we review models of Leigh’s syndrome (LS)
and Alzheimer’s disease, as well as the Warburg effect in can-
cer. Importantly, some of the key processes that are simulated or
highlighted may still be localized or related to the mitochondria,
but these studies do not restrict their focus to the organelle and
instead attempt to capture global cellular metabolism related to
energy production.
OVERVIEW OF CONSTRAINT-BASEDMODELING
CB modeling is a mathematical representation of the chemical
reaction rates (i.e., flux) through metabolic reactions in a living
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FIGURE 1 | CB modeling of energy metabolism. Constraints and
condition-specific parameters are most commonly represented as
bounds on the flux through reactions in the network; optimizing for
specific cellular objectives identifies network states that satisfy
constraints and simulate in vivo or in vitro metabolism. Computational
tools can be used to analyze models and investigate metabolic
capabilities. The center panel highlights important components of
cellular energy metabolism.
system. The stoichiometry of the biochemical network is depicted
in the form of a stoichiometric matrix S, in which rows represent
metabolites and columns represent reactions. For each reaction,
the metabolites consumed (i.e., substrates) are represented by
negative coefficients, whereas positive coefficients indicate pro-
duction of metabolites; all metabolites that do not participate in
a reaction are assigned a zero coefficient, resulting in a sparse
matrix. S provides the relationship between reaction activity and
metabolite concentration change as Sv = dx/dt, where the vector
v represents the flux through each reaction, and concentrations of
all metabolites are represented by vector x. In this way, the num-
bers in S impose stoichiometric constraints on reaction fluxes,
where the net change of each metabolite is a direct function of the
reactions in which it participates. Often, the system is assumed to
be in a net mass-balanced quasi-steady state that is represented by
Sv = 0. Lower and upper bounds (vmin ≤ v ≤ vmax) are imple-
mented to enforce directionality and capacity constraints for each
reaction.
In mathematical terms, the constraints define a multi-
dimensional solution space of flux distributions for a specified
condition that are consistent with the available data. While addi-
tional constraints such as metabolite concentrations and localiza-
tion can further shrink the solution space, the system typically
remains under-determined, with many alternative flux distri-
bution solutions that satisfy Sv = 0. By optimizing a relevant
objective function, thereby driving network flux toward the pro-
duction or consumption of a defined set of metabolites, a single
distribution v that satisfies the objective can be found. Often,
an objective function is chosen to replicate the assumed in vivo
biological selection pressure, whether this is maximum ATP pro-
duction, maximum biomass production or other. In practice,
the objective function is specified by vector c, with weights
representing the relative contribution of each reaction. Linear
programming can then be used to identify an optimal flux dis-
tribution that satisfies all constraints. Notably, there are typically
many equivalent optimal solutions, and so the internal state of
the network found to be optimal is usually not unique (Papin
et al., 2002; Price et al., 2002; Reed and Palsson, 2004). The exer-
cise of constraining the flux through a metabolic network using
the Smatrix, steady-state assumption, and defined bounds, along
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with calculating the optimal distribution of flux through all reac-
tions for a given objective function, is called Flux Balance Analysis
(FBA). This approach can be summarized mathematically as
follows:
Maximize cTv
subject to :
Sv = 0
vmin ≤ v ≤ vmax
One of the major advantages of FBA is that it can be applied
to large-scale metabolic networks, where a phenotype is an end
result of activities of many biochemical reactions. A flux through
each reaction can be calculated, and patterns of consumption
and production of each metabolite can be predicted, even for
systems with tens of thousands of components. Additional meth-
ods such as Flux Variability Analysis (FVA) (Orth et al., 2010) or
Monte Carlo sampling of solution spaces (Almaas et al., 2004;
Price et al., 2004) can address the variability possible in each of
these computed reaction fluxes as well. Importantly, kinetic infor-
mation such as enzyme concentrations is not required, although
this information—when incorporated into more advanced FBA-
based frameworks—will certainly facilitate accurate calculation of
the in vivo relevant flux distributions. Another advantage is that
FBA can be used to perform simulations under varied conditions
simply by altering the constraints such as substrate availability or
ATP production.
The accuracy of CB models depends in part on how well the
S matrix represents the actual biochemical network of the liv-
ing system. Therefore, construction of S for a specific organism is
an important, data-intensive, and often arduous procedure. The
process starts with collecting species-specific data from various
sources such as genome annotations, high-throughput experi-
ments, and relevant literature of the biochemistry and physiology
of the organism. This leads to a draft network that must then
be gap-filled (Reed et al., 2006; Kumar et al., 2007) and updated
until it can be used to simulate phenotypes, thereby establish-
ing a computable in silico model. For example, predicted flux
through a defined biomass reaction can be interpreted as cel-
lular growth; likewise, environmental or genetic conditions that
block flux through this reaction are considered “lethal.” With a
computable model, predictions of phenotypes (based on reac-
tion fluxes) such as knockout lethality, growth rates on different
substrates, and/or byproduct section rates can be compared to
experiment, and the model can thus be iteratively tested and
improved. Context-specific information is then imposed on the
network to either simulate different conditions in silico, or—
for higher organisms—to establish a representative model for
some subset of the global species network (Becker and Palsson,
2008; Jerby et al., 2010; Rolfsson et al., 2011). For example, for
a mitochondrial model, only those reactions and metabolites
localized to or associated with mitochondria are utilized; for a
brain-specific model, only metabolic enzymes corresponding to
genes expressed in brain tissue are used. The context-defining
constraints are imposed as upper and lower bounds on reactions
in the model, or by the inclusion or removal of specific genes
and reactions. These bounds and the determination of whether
network components are present or absent can be based on exper-
imentally calculated values, or inferred through a computational
approach, such as those available in the COBRA Toolbox (Orth
et al., 2010). The main objective of all constraints applied to the
reaction network is to simulate in vivo conditions as precisely as
possible. With the development of better high-throughput mea-
surement tools, and the consequent generation of more plentiful
and more precise data, the S matrix and associated constraints
will become more accurate.
MODELING MITOCHONDRIALMETABOLISM AND
DISEASE-RELATED ABERRATIONS
In this section, we review studies that focus on CB models of
normal and malfunctioning mitochondria. As described above,
the exercise typically starts with building a framework of reac-
tions and applying constraints to mirror normal or disease states.
After a model has been sufficiently refined, an objective function
is established (e.g., ATP production), and FBA is performed to
simulate mitochondrial function.
In 2002, Ramakrishna and Palsson characterized the opti-
mal flux distributions for maximal ATP production in a
mitochondria-specific metabolic network, which included gly-
colytic pathways, the citric or TCA cycle, and the electron trans-
port system (ETS). ATP production and the concomitant O2
uptake rates were then simulated for three common substrates:
glucose, lactate, and palmitic acid. Their results showed that the
model could uptake glucose to produce 38 moles of ATP with the
concomitant utilization of 6 moles of O2; lactate uptake corre-
sponded to 17.5 moles of ATP with the utilization of 3.0 moles of
O2, and palmitic acid uptake (a 14-C fatty acid) led to 129 moles
of ATP, but required 23 moles of O2, which is in agreement with
experimental values.
Extending the analysis further, the authors simulated changes
in ATP production as a result of mutations in genes encoding TCA
cycle enzymes (i.e., by constraining flux through associated reac-
tions to zero). Mutations in TCA enzymes such as α-ketoglutarate
dehydrogenase, fumarase, and succinate dehydrogenase have been
implicated in mitochondrial diseases (Bourgeron et al., 1994;
Rustin et al., 1997). The authors also simulated a loss of activ-
ity for each enzyme individually by sequentially inactivating the
corresponding reaction in the TCA cycle. Deletions of all sequen-
tial enzymes led to no production of ATP. However, with only the
α-ketoglutarate dehydrogenase deletion, the model predicted a
reduced ATP yield and excess production of α-ketoglutarate. The
results of this simulation were in agreement with experimental
observations (Rustin et al., 1997).
The study presented by Ramakrishna and Palsson focused
entirely on mitochondrial processes involved specifically in ATP
production. In 2004, Vo et al. constructed an enhanced metabolic
model, in which they expanded to additional mitochondrial func-
tions. In addition to ATP production, they also studied heme and
mixed phospholipid biosynthesis, utilizing proteomics, and bio-
chemical data from human cardiac mitochondria (Ozawa et al.,
2003; Taylor et al., 2003).
The resulting model included 189 reactions and 230 metabo-
lites, and all reactions were elementally and charge balanced.
The list of processes included the TCA cycle, OxPhos, fatty acid
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β-oxidation, phospholipid biosynthesis, urea cycle, and reactive
oxygen species (ROS) detoxification. Each reaction and metabo-
lite was assigned to its respective compartment such as mitochon-
dria, extracellular space, or cytosol. In addition to the localization
data, a confidence score was assigned to each reaction based on
the data supporting it. For example, the highest confidence of 4
was assigned to a reaction supported by biochemical data, and
the lowest confidence (0) to reactions with in silico evidence only.
One of the salient features of the model was that the majority of
the reactions in the network were assigned high confidence scores,
indicating that the model was experimentally well supported.
Thismodel was used to simulate ATP production and calculate
yield from three energy sources: glucose, fatty acids, and amino
acids. The model produced 31.5 ATPs for each mole of glucose.
For calculating ATP yield from fatty acids, the authors focused
only on palmitate and calculated that each mole of palmitate led
to production of 106 ATPs, which is different from the value of
129 reported in the literature (Lehninger et al., 1993). While cal-
culating ATP yield from amino acids, glutamate was selected as
the substrate; the yield was calculated to be 20.5 ATPs/mol of glu-
tamate. Results for heme biosynthesis, amino acid metabolism
and phospholipid simulations were similar to the experimen-
tal observations (Sedman et al., 1982) further validating the
model.
In addition to modeling biological processes, the authors
studied network characteristics such as network flexibility and
correlated reaction sets. In order to analyze flexibility, FVA was
performed. FVA calculates minimal and maximal boundaries for
fluxes through each reaction in the network, such that the optimal
solution is still satisfied. This analysis revealed that the solu-
tion space for optimal ATP production is restricted compared to
heme and phospholipid biosynthesis objectives, indicating that
the former is a highly coordinated biological function with a
narrower set of possible network states satisfying optimal pro-
duction. Another interesting aspect that was investigated in this
study was the exploration of correlated sets of reactions. While
calculating alternate optima, authors identified a set of reactions
with highly correlated flux distributions across various objective
functions representing multiple mitochondrial functions. These
highly correlated sets are candidates to be potentially co-regulated
in the cell.
A subsequent study (Thiele et al., 2005) further refined
this mitochondrial metabolic model and used it as a tool to
assess metabolic states by integrating available experimental
measurements under different physiological conditions: nor-
mal, diabetic, ischemic, and different diets. They also stud-
ied the impact of suggested treatments on mitochondrial
energy metabolism under diabetic conditions. The authors
employed linear programming and uniform sampling techniques
to identify candidate steady states and to characterize network
properties under physico-chemical and experimentally defined
constraints.
One of the key modifications made in (Thiele et al., 2005)
to the previous mitochondrial model was the addition of ketone
body degradation reactions. This addition was important because
diabetes leads to high concentrations of ketone bodies in the
blood. In simulations, this study generated candidate steady-state
flux distributions for different metabolic states, such as dia-
betes, ischemia, normal, and different diets. Different states were
classified based on the experimental or measured values of reac-
tions exchanging (uptake or secretion) metabolites between the
cell and the surrounding environment; these values determined
constraints on the exchange reactions in the model, thereby
enforcing the different metabolic states. For example, for sim-
ulating diabetes, mitochondrial fatty acid uptake through the
carnitine palmitoyl-transferase (CPT-1) shuttle was increased,
which reflects the increased uptake observed in diabetes. Similar
constraints, such as normalized glucose or normalized ketone
body uptake rates, were applied to reflect other metabolic states.
This was an excellent example of how CB modeling can be
used to simulate intracellular conditions in normal and diseased
states.
Using uniform sampling of the steady-state flux space for the
four constrained mitochondrial models, the authors calculated
the flux distribution (in this case, the frequency of observed flux
values over all random samplings, as opposed to the set of fluxes
calculated in one instance of FBA for all reactions in the network)
for various reactions such as lactate exchange, ATP demand, oxy-
gen exchange, and others. The sampling technique produced a
range of allowable metabolic network states that represented pos-
sible steady-state flux distributions of the network for all four
states, defined using constraints from experimentally measured
conditions. Results of this analysis showed that there is reduced
network flexibility in diabetes, and changes in oxygen levels or
ATP can greatly affect mitochondrial metabolism.
One of the unique features of this study was that the authors
modeled therapeutic approaches for ischemia and predicted the
effectiveness of these approaches based on network simulations.
Predictions agreed remarkably well with the observed side effects
of these therapies; for example, one of the therapeutic approaches
suggested previously for ischemia was to increase glucose uptake
(Apstein, 1998) in the hopes of increasing the availability of ATP.
However, the analysis of candidate flux distributions predicted
that this therapy would not change the disease metabolic state,
but rather would lead to higher production of lactate, which was
the known side effect.
Additionally, the model predicted that the oxygen require-
ments for the cardiac myocyte were much more constricted to
be near maximal under typical diabetic conditions. This find-
ing provided a possible mechanistic explanation for the clinical
observation that ischemic events, which limit oxygen, are more
likely to be fatal for patients with diabetes than for unaffected
people (Taegtmeyer et al., 2002). Another intriguing outcome
of this analysis was that flux through pyruvate dehydrogenase
was predicted to be near zero under typical diabetic condi-
tions. The gene encoding pyruvate dehydrogenase had earlier
been found to be a highly differentially expressed gene in tran-
scriptomics studies (Stanley et al., 1997). From transcriptomics
analyses alone, it can be difficult tell the difference between
gene expression changes that are causal or passenger—or, in
particular, what changes might lead to a restoration of the
system. In this example, the model clearly suggested that the
much lower expression value of the pyruvate dehydrogenase-
encoding gene is a down-regulation response of the cell, which
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is appropriate to the metabolic conditions in the surrounding
blood of a typical diabetes patient. Thus, engineering, for exam-
ple, an increase in the expression of this gene to restore it to
its normal state would be doomed to fail—there are actually
no possible steady-state flux distributions in the mitochondrial
metabolic network for which this reaction could be used, given
the availability of surrounding metabolites. This is one exam-
ple of how mechanistic models can help decipher what might be
causal disease perturbations, and what might be potential ther-
apeutic interventions, from those that are not. They can also
help to discern what changes in the expression state of a sys-
tem might be a disease perturbation from what seems to be
an appropriate response of the system to compensate for the
perturbation.
More recently, a heart mitochondrion model (iAS523) was
reconstructed (Smith and Robinson, 2011), in which metabo-
lites were made part of the model only if they were consumed
or produced in the mitochondria. Information from MitoMiner,
a mitochondrial proteomics database, was utilized for estab-
lishing the address of each metabolite in the cell. Constraints
applied to the model were chosen from the literature to mimic
conditions specific to the heart. The model was then refined
iteratively by incorporating information from multiple sources.
For testing the predictive abilities of the model, the authors
simulated three disorders of, or related to, the TCA cycle: (1)
fumarase deficiency (OMIM: 606812), (2) succinate dehydro-
genase deficiency (OMIM: 252011), and (3) α-ketoglutarate
dehydrogenase deficiency (OMIM: 203740). The authors ran sim-
ulations for various mitochondrial functions with constraints
specific to each disorder. The model predicted ATP production
accurately for all diseases, especially for the fumarase deficiency
disorder.
In fumarase deficiency disorder, fumarase (fumarate
hydratase) is completely shut down; the TCA cycle thus
ends at the step where fumarate would normally be converted
to malate by fumarase, leading to accumulation of the former.
The TCA network structure with this disorder precludes ATP
production in the heart, however, patients with this disorder do
not present with heart defects. To investigate this discrepancy,
authors simulated elevated metabolism by removing the bound-
ary constraints on all metabolites. Through this process, they
identified that increased concentration of certain metabolites,
such as glutamate, aspartate, or valine, lead to increased ATP
production in the TCA cycle. This result agrees with findings in
the literature (Bourgeron et al., 1994), suggesting that there is a
bypass through which metabolites are exported out of the mito-
chondrial matrix into the cytosol. The malate-aspartate shuttle
(Figure 2) is the bypass reaction that exports metabolites out of
the mitochondria. Because of this bypass, fumarase deficiency
does not fully shut down the TCA cycle, but instead only reduces
ATP production. The effect of aspartate uptake was even more
pronounced than the increased uptake of glucose, suggesting
that providing excess of the former may best reduce the effect of
fumarase deficiency. Increasing the uptake of asparate and serine
was suggested as a therapeutic strategy, but it remains to be seen
if the aspartate uptake levels can be replicated in vivo; however,
this in silico result is an experimentally testable hypothesis.
FIGURE 2 | Schematic of the major metabolic processes housed in the
mitochondria, and detail of the TCA cycle and the GABA shunt (GABA
shunt related reactions in purple). AcCoA, acetyl coenzyme A; ADP,
adenosine diphosphate; aKG, α-ketoglutarate; ATP, adenosine triphosphate;
Cit, citrate; Fum, fumarate; GABA, γ-aminobutyric acid; Glu, glutamate; iCit,
isocitrate; Mal, malate; NADH, nicotamide adenine dinucleotide; OA,
oxaloacetate; Pyr, pyruvate; Succ, succinate; SuccCoA, succinyl-coenzyme
A; Sucsal, succinate semialdehyde.
MODELING ENERGY METABOLISM IN NEURODEGENERATIVE
DISORDERS
Defects in energy metabolism have been implicated in various
neurodegenerative diseases such as LS, Alzheimer’s disease, and
Parkinson’s disease. Here, we present modeling efforts studying
neurodegenerative diseases in relation to defects in ATP produc-
tion in mitochondria.
In 2007, Vo et al. published a model for LS and suggested a
framework for employing CB modeling to recommend a treat-
ment strategy for this disease. The authors modeled the status
of mitochondrial processes in LS by constructing a model for
LS-affected fibroblasts and normal fibroblasts, utilizing experi-
mental measurements such as substrate uptake, metabolite secre-
tion rates, and isotopomer data. The authors experimentally
grew normal and LS cells in media with 13C-labeled glucose and
identified the distribution of metabolites containing labeled glu-
cose through gas chromatography-mass spectrometry (GC-MS).
The study revealed that although LS-affected cells have slower
metabolism as compared to normal cells, their ATP production
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rate was similar to that of the normal cells. Additionally, LS-
affected cells exhibited a narrower flux range for the reactions
involved in ATP production. This work implicated mutations in
succinate cytochrome c reductase and defective respiratory com-
plex II as themost likely candidates for inducing LS in the cell line,
ruling out malfunction of ATP synthase, pyruvate dehydrogenase
complex, or respiratory complexes I, III, and IV as likely causes of
the disease. Another impressive aspect of this study was that the
authors suggested an effective vitamin treatment for LS patients.
Predictions of the model were confirmed in vitro with experi-
mental measurements in both cell lines. This study is a prime
example of how the inclusion of a multitude of experimental data
can enhance the accuracy of in silico models and can suggest an
effective treatment regime for a complicated disease such as LS.
Mitochondria-centric network models have been recon-
structed now for three different subtypes of neurons (Lewis et al.,
2010), and used to simulate the relationship between Alzheimer’s
disease and the TCA cycle. Utilizing genomics, proteomics and
literature-based data, Lewis et al. curated three cell type-specific
canonical models representing cholinergic, GABAergic, and glu-
tamergic neurons that were coupled to astrocytes via interstitial
space; neuron and astrocyte metabolism were subdivided into
cytosolic and mitochondrial compartments. This was the first
large-scale CB modeling of multicellular metabolic interactions
between astrocytes and neurons, and also the most detailed model
for brain energy metabolism to date. Authors simulated produc-
tion of ATP to test the accuracy of the model, and calculated the
predicted values to be within 8% of published values. To inves-
tigate the previously reported relationship between Alzheimer’s
and distorted activity of TCA cycle enzymes (Reiman et al., 2004),
the authors modeled the effect of mitochondrial α-ketoglutarate
dehydrogenase (AKGDm) mutation on ATP production in all
three models.
Results showed impaired OxPhos in cholinergic and glutamer-
gic neurons; however, the GABAergic neuron model did not
show any decrease resulting from the simulated AKGDmdysfunc-
tion. Investigating further, the model predicted that the GABA
shunt (Figure 2) was carrying the flux obstructed by mutated
AKGDm. The GABA shunt includes a gene glutamate decarboxy-
lase (GAD), and analysis suggested that isoforms of GAD could
provide protection to GABAergic neurons. In these neurons, GAD
carried flux, whereas in the other two neurons, GAD was absent,
entailing greater susceptibility to dysfunctional AKGDm. These
results were corroborated with expression data from Alzheimer’s-
affected brain regions, where underexpression of GAD was found
in the affected regions, and overexpression in the unaffected
regions. Pathway analysis on the microarray data from differ-
ent regions of the Alzheimer’s-affected brain revealed that four
regions (posterior cingulate cortex, middle temporal gyrus, hip-
pocampus, and entorhinal cortex)_had lower metabolic rates
in Alzheimer’s disease also showed decreased rates of glycolysis
and TCA.
In addition to TCAmodeling, Lewis et al. investigated the rela-
tionship between acetylcholine and mitochondrial metabolism.
Studies have shown that the cytosolic acetyl-CoA needed to
produce the neurotransmitter acetylcholine originates in the
mitochondria. Earlier, Watson and Craft (2004) had reported
that an increase in glucose uptake leads to improved cogni-
tion in Alzheimer’s patients, further demonstrating a relationship
between energy metabolism in the mitochondria and the gen-
eration of cytosolic acetylcholine. Using CB modeling, authors
identified two pathways that were involved in the indirect trans-
port of mitochondrial acetyl-CoA into the cytosol. Specifically,
singular value decomposition was applied to a collection of 21,000
feasible reaction sets, yielding three pathways that allow for cou-
pling of mitochondrial acetyl-CoA and cytosolic acetylcholine;
two of these pathways, involving citrate or acetoacetate as carriers,
respectively, were supported by omics data and enzyme localiza-
tion. Through random sampling, the CB model showed a strong
correlation between mitochondrial pyruvate dehydrogenase and
cytosolic choline acetyltransferase, the enzyme that produces
acetylcholine from acetyl-CoA, consistent with the experimen-
tally observed coupling (Ragozzino et al., 1998). Furthermore,
reaction fluxes in each of the two acetyl-CoA transport pathways
were also significantly correlated with choline acetyltransferase.
Using their model, Lewis et al. were able to identify poten-
tial connecting pathways between mitochondrial metabolism and
acetylcholine production, and subsequent analysis also revealed
that cholinergic neurotransmission likely depends on redundancy
among these pathways.
Taken together, this study presented a workflow of construct-
ing a model through an iterative process of hypothesis generation
and incorporation of experimental data, leading to neuron mod-
els coupled to astrocytes with superior predictive power.
MODELING THEWARBURG EFFECT IN CANCER
The Warburg effect, named after Otto Warburg, has been
observed in many cancers and fast dividing cells, and is charac-
terized by a switch from OxPhos—the normal route of energy
production—to a combination of OxPhos and aerobic glycoly-
sis. Glycolysis is a relatively inefficient way of producing ATP,
typically utilized in the absence of oxygen, and leads to produc-
tion of lactic acid. Although the Warburg effect was reported in
1956 (Warburg, 1956), the biological reasons and advantages of
this switch to increased glycolysis in cancerous cells, even when
oxygen is available, remain unclear. It has been proposed that
aerobic glycolysis leads to increased biomass production, which
would facilitate rapid proliferation of cancerous cells [reviewed
by Vander Heiden et al. (2009)]. Lately, CB modeling of global
metabolic processes—including both mitochondrial and cytoso-
lic pathways—has been employed by various researchers to help
reveal the underlying mechanisms for the Warburg effect in
proliferating cells.
In 2010, a model simulating the Warburg effect (Vazquez
et al., 2010) showed that aerobic glycolysis is favored by rapidly
dividing cells because of (1) high glucose uptake capacity and
(2) the solvent capacity of components allocated by the cell to
OxPhos. Specifically, the authors explained the solvent capacity
constraint as the maximum volume of the cell that is avail-
able for OxPhos enzymes. Higher glucose uptake will force the
allocation of more resources toward ATP production; however,
because of the solvent capacity constraint, the cell cannot increase
the concentration of enzymes in the mitochondria, so this leads
to inefficient production of ATP via glycolysis reactions in the
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cytosol. The author explained the solvent capacity constraint as
the maximum volume of the cell that is available for OxPhos
enzymes. This suggested that limited volume forces the cell to
switch to aerobic glycolysis. Vazquez and Otalvi later argued that
the cell instead switches to aerobic glycolysis because, for rapidly
dividing cells, ATP demand is high and aerobic glycolysis provides
higher ATP yield per volume density (Vazquez and Oltvai, 2011).
They posited that energy demand is the only driving force for the
existence of the Warburg effect in rapidly proliferating cells and
argued against the need for metabolite precursors or biomass for
the switch to aerobic glycolysis. Both studies were focused mainly
on catabolic efficiency as the driving force behind the Warburg
effect, and the Vazquez model was limited to energy metabolism
reactions.
In 2011, Shlomi et al. used a genome-scale model of human
metabolism (Duarte et al., 2007) to focus both on anabolic and
catabolic aspects of the Warburg effect (Shlomi et al., 2011).
Their model predicted three distinct growth states as suggested
by the experimental observations (Ramanathan et al., 2005): (1)
low OxPhos with almost no glycolysis; (2) high OxPhos with
low glycolysis; and (3) low OxPhos with high glycolysis. The first
and third states had already been reported; however, the notable
feature of these predictions was the second state, which was a
hybrid of normal cell energy metabolism and aerobic glycoly-
sis. Utilizing a previously constructed model of global human
metabolism (Duarte et al., 2007) to focus on this mitochondrial
process, authors constrained the model by using enzyme con-
centrations that were computed from catalytic rates reported in
published literature. Using different glucose uptake rates, energy
production was maximized, and the results showed that it is cost-
effective for the cell to switch to aerobic glycolysis when glucose
uptake is unlimited. Cost was calculated as the enzyme concen-
tration required per unit of glucose uptake. Authors computed
the cost efficiency by comparing the ratio of ATP yield to cost
under high glucose and optimal glucose uptake. Quantitatively,
even though there was high growth (optimum glucose uptake
condition), the cost to produce that growth was also high; for
low growth (unlimited glucose uptake condition), the cost associ-
ated to produce growth was also very low. This was an interesting
observation suggesting that the Warburg effect is an adaptation
by a cell to be more efficient in utilizing the available resources
both in catabolism and anabolism. This study also showed that
by adding more biochemical constraints to the model, the accu-
racy of CBmodeling could be increased, and the inherent strength
of CB modeling in simulating a living system through linear
equations could be exploited.
CONCLUSIONS
Metabolic processes involved in energy production, especially
those localized to mitochondria, have been extensively studied in
relation to multiple pathologies. CBmodeling has been applied to
help understand the intricacies of biological processes in normal
FIGURE 3 | Future areas of focus for CB modeling of mitochondrial
metabolism. Depicted here are several potential research areas that will be
explored in future modeling endeavors, including the effects of (1) metabolite
exchange between mitochondria and other compartments; (2) dynamic
mitochondrial populations, in terms of size and age; and (3) free radical
induced mutations in mitochondrial DNA.
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and deviant mitochondria, and provides a promising approach
with potential to ultimately help guide therapeutic approaches
for diseases. In the future, with the increased availability of more
detailed experimental data, such as proteomic and metabolomics
data, models will be refined, and their predictive power will be
enhanced significantly.
Additionally, we expect that several other research areas
(Figure 3) will enhance the connections between mitochondrial
models and human disease. For example, models simulating the
effects of the free radicals on mitochondrial functions, especially
energy production, will likely mature into a valuable avenue of
research. Free radicals cause mutations in mitochondrial DNA
andmitochondria accumulate mutations as they age. Data-driven
and mechanistic models that can simulate the effects of free rad-
icals on mitochondrial functioning should further illuminate the
pathogenic effect of resulting mutations on the emergence of
disease. We also expect that CB models will be developed to
more rigorously model the effects of inter-organelle metabolite
trafficking on energy metabolism in mitochondria. Metabolite
trafficking between mitochondria and other organelles, such as
the endoplasmic reticulum, microsomes, and others, plays a crit-
ical role in energy metabolism in the cell. Normal functioning
of a cell is contingent upon the dynamic exchange of metabo-
lites between these organelles, and errors in transport can cause
disease (Papin et al., 2002; Price et al., 2002).
Until now, models have considered mitochondrial processes in
terms of representative activity of a single mitochondrion. In the
future, we expect CB modeling to be used to simulate changes
in the size and characteristics (e.g., age of mitochondria) of het-
erogeneous mitochondrial populations in the cell, in order to
analyze effects on energy production from dynamic changes in
mitochondria in cells. Changes in mitochondrial population, as
well as errors in their turnover in the cell, have been implicated
in several diseases (Schon and Przedborski, 2011). Finally, as the
CB modeling field evolves, strategies will develop to simulate
behavior of entire cell populations in organs or organ systems in
disease and normal states, as well as in response to therapeutics.
This will include simulating mitochondrial and other energy-
related functions in different cell types in the same organ, and
could incorporate information regarding various morphological
features such as mitochondrial and/or cell density, extracellular
matrix composition, and physico-chemical characteristics such as
availability of metabolites.
Focus areas mentioned above either singularly or cumulatively
have the potential to reveal the intricacies of energy metabolism
in mitochondria and in relation to emergent physiology and
disease. The goal of CB modeling is to accurately and compre-
hensively simulate facets of energy metabolism and its effect on
disease. Models with high predictive accuracy require accurate
and precise context-specific biological measurements. As technol-
ogy and experimental procedures continue to improve, providing
more data and at higher resolution, CB modeling will present an
important avenue to contribute toward the understanding and
the treatment of energy and mitochondrial metabolism-based
diseases.
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